	BCAA No BCAA Events Total Events Total		Risk Ratio			Risk Ratio			
Study or Subgroup			<b>Events Total</b>		Weight M-H, Random, 95%		Year	M-H, Random, 95% CI	
Fan 1994	5	64	9	60	50.3%	0.52 [0.19, 1.47]	1994	9 <del>1              </del> 9	
Meng 1999	4	21	0	23	26.3%	9.82 [0.56, 172.11]	1999	<del>o                                      </del>	
Kikuchi 2016	1	39	0	38	23.4%	2.92 [0.12, 69.64]	2016	25 to 12	
Total (95% CI)		124		121	100.0%	1.69 [0.23, 12.24]			
Total events	10		9						
Heterogeneity: Tau <sup>2</sup> =	1.75; Ch	$i^2 = 4.5$	5, df = 2	P = 0.1	0); $I^2 = 58$	6%	į.	0.005 04 40 300	
Test for overall effect	Z= 0.52	(P = 0.6)	60)				9	0.005 0.1 1 10 200 Favours BCAA Favours no BCAA	

## Supplementary Figure 1 Forest plot showing 90-d postoperative mortality. BCAA:

Branched chain amino acid; CI: Confidence interval.

Database	Search terms	No.	of				
		results					
PubMed	(BCAA* OR "Branched-chain amino acid*" OR "Branched	2151					
	chain amino acid*" OR "Amino Acids, Branched-						
	Chain" [Mesh] OR Branched-chain OR "Branch chain*" OR						
	Leucine or Valine or Isoleucine)						
	AND						
	(liver OR hepatic OR hepatocellular OR HCC OR						
	"Carcinoma, Hepatocellular" [Mesh])						
	AND						
	(resection OR surgery OR surgical OR operation OR excision						
	OR preoperative OR pre-operative OR perioperative OR						
	peri-operative OR postoperative OR post-operative OR "post						
	operative" OR curative OR hepatect* OR						
	"Hepatectomy" [Mesh] OR segmentectom* OR lobectom* OR						
	transplant* OR proced* OR "Liver Transplantation" [Mesh])						
Embase	(bcaa* OR 'branched-chain amino acid*' OR 'branched chain	2840					
	amino acid* OR 'branched chain amino acid'/exp OR						
	'branched chain' OR 'branch chain' OR leucine OR valine OR						
	isoleucine)						
	AND						
	(liver OR hepatic OR hepatocellular OR HCC OR 'liver cell						
	carcinoma'/exp)						
	AND						
	(resection OR surgery OR surgical OR operation OR excision						
	OR preoperative OR 'pre operative' OR perioperative OR						

'peri operative' OR postoperative OR 'post operative' OR curative OR hepatect\* OR 'hepatectomy'/exp OR segmentectom\* OR lobectom\* OR transplant\* OR 'liver graft'/exp OR proced\*)

Scopus

(bcaa\* OR "Branched-chain amino acid\*" OR "Branched chain 2364 amino acid\*" OR branched-chain OR "Branch chain\*" OR leucine OR valine OR isoleucine)

AND

(liver OR hepatic OR hepatocellular OR HCC)

**AND** 

(resection OR surgery OR surgical OR operation OR excision OR postoperative OR post-operative OR "post operative" OR pre-operative)//(bcaa\* OR "Branched-chain amino acid\*" OR "Branched chain amino acid\*" OR branched-chain OR "Branch chain\*" OR leucine OR valine OR isoleucine)

AND

(liver OR hepatic OR hepatocellular OR HCC)

AND

(preoperative OR perioperative OR peri-operative OR curative OR hepatect\* OR segmentectom\* OR lobectom\* OR transplant\* OR proced\*)

## Cochrane Library



192

Web of (bcaa\* OR "Branched-chain amino acid\*" OR "Branched chain 477

Science amino acid\*" OR branched-chain OR "Branch chain\*" OR leucine OR valine OR isoleucine)

AND
(liver OR hepatic OR hepatocellular OR HCC)

AND
(resection OR surgery OR surgical OR operation OR excision OR postoperative OR post-operative OR "post operative" OR pre-operative OR preoperative OR perioperative OR perioperative OR perioperative OR perioperative OR perioperative OR transplant\* OR proced\*)

BCAA: Branched chain amino acid; HCC: Hepatocellular carcinoma.

## Supplementary Table 2 Population, intervention, comparison, outcomes and study inclusion and exclusion criteria

	Inclusion criteria	Exclusion criteria
Population	Patients diagnosed with liver	Patients undergoing surgery for
	cancer, and being planned for	indications other than liver
	or have undergone liver	cancer
	surgery for treatment of liver	
	cancer	Patients undergoing procedures
		such as radiofrequency ablation
		and transarterial
		chemoembolisation only
Intervention	Patients with branched chain	
	amino acids supplementation	
	pre-operatively or post-	
	operatively	
Comparison	Patients in control arm with	Patients in control arm with any
	normal diet prescribed pre-	other form of oral nutritional
	operatively and post-	supplementation pre-operatively
	operatively for study follow-up	or post-operatively
	duration	
Outcomes	Perioperative (morbidity,	
	mortality and length of stay)	
	and oncological (recurrence	
	and overall survival)	
Study type	Articles in English or	Mixed methods research, meta-
	translated to English	analyses, systematic reviews,
		case-control studies, cross-
		sectional studies and descriptive

papers

High-quality longitudinal Studies published in any cohort studies or trials or language other than English, and randomized-controlled trials do not have an English translation

Supplementary Table 3 Definition of mortality outcomes in included studies

Ref.	Mortality	Intervention		Control		Follow-up time <sup>1</sup>			
	definition								
		Sample size	No. of	Sample size	No. of	Intervention	Control		
			deaths		deaths				
Hachiya <i>et al</i> <sup>[39]</sup> , 2020	Calculated from	74	2	80	5	21.8 mo	NR		
	4-yr survival rate								
	survival								
Ichikawa <i>et al</i> <sup>[40]</sup> , 2013	Calculated from	26	4	30	3	39.5 mo	36.0 mo		
	4-yr survival rate								
	survival								
Kobayashi <i>et al</i> <sup>[36]</sup> ,	Calculated from	26	6	10	4	NR	NR		
2019	5-yr survival rate								
	survival								
Meng et al <sup>[31]</sup> , 1999	Mortality at last	21	7	23	4	511.6 d	512.7 d		
	follow up								
Nagasue <i>et al</i> <sup>[32]</sup> , 1997	Mortality at last	67	34	65	32	35.8 mo (17.9)	36.0 m		
	follow up						(17.7)		
Okabayashi <i>et al</i> <sup>[35]</sup> ,	Mortality at last	40	9	72	13	16.3 mo	23.3 mo		
2008	follow up								

<sup>&</sup>lt;sup>1</sup>Data is expressed as n or mean +/- SD (median, range)

## Supplementary Table 4 Comparison of Aminoleban EN and livact

BCAA	Company of	Country of	City of	Dosage	Composition					
	manufacture	manufacture	manufacture							
					L-	L-leucine	L-valine	Lipid (g)	Carbohydrate	
					Isoleucine	(mg)	(mg)		(g)	
					(mg)					
Aminoleban	Otsuka	Thailand	Samut	50 g/packet	1922.5	2037	1602	3.7	31.5	
EN			Sakhon							
Livact	Ajinomoto	Japan	Tokyo	4.15 g/packet	952	1904	1144	NIL	NIL	

BCAA: Branched chain amino acid; NIL: Nothing.